AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in

Read the full 177 word article

User Sign In